The effect of ketanserin on the symptoms of 21 patients with stable intermittent claudication was examined in a double-blind, placebo-controlled, parallel-group study. Benefit was assessed by repeated treadmill exercise tests, recording claudication and total walking times. After three months' treatment with ketanserin (mean dose 167 mg/day) there was no significant change in claudication time (mean change +12%, 95% CI -9; +33%) or total walking time (mean change -14%, 95% CI - 47%; + 19%). The confidence intervals show that ketanserin treatment is unlikely to be associated with clinically important improvement.
Get full access to this article
View all access options for this article.
References
1.
DeCree J., Leempoels J., Geuken H., Verhagen H.: Placebo-controlled double-blind trial of ketanserin in treatment of intermittent claudication. Lancetii:775-779, 1984.
2.
Bounameaux H. , Holditch T., Hellemans H., et al: Placebo-controlled, double-blind, two centre trial of ketanserin in intermittent claudication. Lancetii:1268-1271, 1985.
3.
Ramsay LE: Ketanserin in intermittent claudication. Lanceti:619, 1986.
4.
Armitage P.: Statistical Methods in Medical Research. Oxford, England, Blackwell Scientific Publications, 1977.
5.
Gill J., Zezulka AV, Beevers DG, Davies P.: Relation between initial blood pressure and its fall with treatment. Lanceti:567-569, 1985.
6.
McAreavey D. , Lorimer AR, Reid JL, et al: "Third-drug" trial. Br Med J288:1008-1009, 1984.
